This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DiaDexus Highlights Outcome Study Showing A Reduction Of Lp-PLA2 Activity Was A Highly Significant Predictor Of Reduction In Subsequent Coronary Events

diaDexus, Inc. (OTCQB:DDXS) highlighted today the published observation that a reduction in Lp-PLA 2 (lipoprotein-associated phospholipase A 2) levels while on a statin treatment can reduce coronary heart disease (CHD) risk. Earlier this month, the Journal of the American Heart Association published the results from a sub-study on the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study of pravastatin in CHD patients.

The sub-study showed that patients who had the biggest drop in Lp-PLA 2 activity levels on pravastatin therapy were most likely to have the greatest benefit, with fewer CHD deaths and heart attacks, as well as significantly fewer total cardiovascular disease events (p<0.001). The majority of the treatment effect (59 percent) was accounted for by changes in Lp-PLA 2 activity, and the authors concluded that this reduction was at least as important as LDL cholesterol (LDL-C) reduction in predicting a favorable response to pravastatin treatment.

“It is well understood that reduction in LDL-C is a key mechanism by which statins reduce risk. This study proves that other mechanisms are also important—reduction in Lp-PLA 2 activity during the first year may account for more than half of the benefits of pravastatin in the LIPID Study,” said Harvey White, DSc, the lead investigator on the study and cardiologist at Auckland City Hospital Green Lane Cardiac Service. “There was a 24 percent (P<0.001) reduction in death from CHD and a 22 percent (P<0.001) reduction in overall mortality observed in this study. These results elevate Lp-PLA 2 to that of a risk factor for CHD.”

“This is one of the first outcome studies to support the value of measuring and lowering Lp-PLA 2 activity to help prevent coronary events,” said Brian Ward, Ph.D., diaDexus’ president and chief executive officer. “The LIPID study used the diaDexus research use only activity assay, which is now a CE marked test, and we anticipate that we will submit the assay for clearance to the FDA.”

About the LIPID Study

The LIPID study ( Long-term Intervention with Pravastatin in Ischemic Disease) was funded by Bristol-Myers Squibb and conducted by the National Heart Foundation of Australia. The sub-study was supported by the National Health and Medical Research Council of Australia and diaDexus.

LIPID was a large (n=9014), double-blind, placebo-controlled study of pravastatin in CHD patients. During a mean 6.0-year follow-up, there were significant reductions in the primary end point of death from CHD, all-cause mortality, and other pre specified cardiovascular end points, including the composite of nonfatal myocardial or CHD death.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs